Plasma Derived Medicine Market - Price, Size, Share & Growth

Plasma is the liquid component of the blood that is of a clear yellowish or light brown color. Plasma-derived medicinal products (PDMPs) are prepared industrially from human plasma and include products such as coagulation factors, albumin, and immunoglobulins which are life-saving therapeutics for several chronic and acute life-threatening diseases such as hereditary coagulation disorders, hereditary immunodeficiency diseases, and others.

The global plasma derived medicine market is estimated to be valued at US$ 33,450 million in 2021 and expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).

Figure 1. Global Plasma Derived Medicine Market Share (%) in Terms of Value, by Product Type, 2021

PLASMA DERIVED MEDICINE MARKET

To learn more about this report, request a free sample copy

Increasing product launches are expected to drive the market growth during the forecast period.

Increasing product launches are expected to boost the growth of the global plasma derived medicine market over the forecast period. For instance, in November 2021, Grifols, S.A., a leading global producer of plasma-derived medicines, announced the launch of albumin ALBUTEIN FlexBag (Albumin [Human] U.S.P.) in 5% and 25% concentrations. ALBUTEIN is derived from plasma and is indicated for cardiopulmonary bypass procedures, hypovolemia, hypoalbuminemia, and plasma exchange.

Plasma Derived Medicine Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 33,450 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	6.8%	2028 Value Projection:	US$ 53,136.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Albumin, Coagulation factors, Immunoglobulins, Others By Indication: Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, Other Orphan Diseases By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG
Growth Drivers:	Increasing use of plasma products in medical applications Increasing product launches Increasing research and development activities
Restraints & Challenges:	High cost of plasma-derived medicines High time required in preparing plasma-derived medicines

Figure 2. Global Plasma Derived Medicine Market Share (%), by Distribution Channel, 2021

PLASMA DERIVED MEDICINE MARKET

To learn more about this report, request a free sample copy

The increasing establishment of new plasma collection centers is expected to drive the market growth during the forecast period.

The increased establishment of new plasma collection centers by the key market players is expected to drive the market growth during the forecast period. For instance, in January 2022, ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced that it had received U.S. Food and Drug Administration (FDA) approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina.

Global Plasma Derived Medicine Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

There is limited knowledge available about plasma-derived therapeutics; however, the COVID-19 pandemic brought attention to this type of treatment and highlighted its potential applications. The key players started carrying out various research activities aimed at determining the use of plasma-derived medicines to treat the COVID-19 infection. For instance, the CoVIg-19 Plasma Alliance was formed in response to the pandemic in April 2020 by major global players in plasma-derived pharmaceutical products market, including LFB, a pharmaceutical company specializing in biological medicinal products, to speed up the development of a hyperimmune immunoglobulin experimental therapy for the treatment of the COVID-19.

However, as a result of the worldwide lockdown, lower volumes of plasma donations began to appear. According to an article published by the National Center for Biotechnology Information (NCBI) in April 2020, the COVID-19 outbreak resulted in a considerable drop in blood donations when compared to the previous year, owing to the COVID-19-related cautions made by the government to avoid crowds, such as lockdowns. Furthermore, the number of asymptomatic cases increased, making it more difficult to diagnose, and consequently, posing an indirect risk to blood collection safety. Increased cases of COVID-19 had also caused widespread fear among blood donors, causing a negative impact on the blood community. Therefore, these factors impacted negatively on the global plasma derived medicine market. However, increasing research activities carried out by researchers are expected to drive the market growth over the forecast period.

Global Plasma Derived Medicine Market: Restraint

The major factors that hinder the growth of the global plasma derived medicine market include the high cost of plasma-derived medicines and high time required in preparing plasma-derived medicines.

Key Players

Major players operating in the global plasma derived medicine market include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG

Frequently Asked Questions

The global plasma derived medicine market is estimated to be valued at US$ 33,450 million in 2021 and expected to exhibit a CAGR of 6.8% between 2021 and 2028.

Factors such as the increasing use of plasma products in medical applications, product launches, and research and development activities are expected to drive the growth of the global plasma derived medicine market during the forecast period.

Immunoglobulins segment is the leading product type segment in the market.

The major factors hampering the growth of the market include the high cost of plasma-derived medicines and high time required in preparing plasma-derived medicines

Major players operating in the market include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG.